Skip to content
Clinical Trials – home
HungaryBack to Hungary

Clinical trials in Deszk – page 12

383 clinical trials in Deszk, Hungary. Every trial is listed in the EU Clinical Trials Register and updated daily.

Deszk at a glance
383
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

383 trials in Deszk

Open in trial search

Arteriosclerosis

Not yet recruiting

Study of olpasiran to prevent first major cardiovascular events in people with high levels of lipoprotein(a)

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Olpasiran
  • Sponsor:Amgen Inc.

Rheumatoid arthritis

Not yet recruiting

Study comparing MB04 (etanercept biosimilar) with Enbrel in patients with moderate to severe rheumatoid arthritis who are taking methotrexate

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Etanercept
  • Sponsor:Mabxience Research S.L.

Psoriasis

Not yet recruiting

Study on the Effectiveness of JNJ-77242113 and Deucravacitinib for Treating Moderate to Severe Plaque Psoriasis in Adults

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Deucravacitinib
  • Sponsor:Janssen - Cilag International

Acromegaly

Not yet recruiting

Phase 2 Study of MAR002 to Assess Safety and IGF‑1 Reduction in Adults with Acromegaly

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Sponsor:Marea Therapeutics Inc.

Colitis ulcerative+1

Not yet recruiting

Study of ABBV-701 and Risankizumab Combination vs Monotherapy in Adults with Moderately to Severely Active Crohn’s Disease or Ulcerative Colitis

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Risankizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Hypoparathyroidism

Not yet recruiting

Study of Encaleret Hemisulfate Hemihydrate for Efficacy, Safety and Tolerability in Adults with Chronic Hypoparathyroidism

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Sponsor:Calcilytix Therapeutics Inc.

Colitis ulcerative+1

Not yet recruiting

Study of risankizumab plus anti‑α4β7 integrin antibody versus each alone in adults with moderately to severely active Crohn’s disease or ulcerative colitis

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Risankizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Type 2 diabetes mellitus

Not yet recruiting

Phase 3 Study of Maridebart Cafraglutide versus Semaglutide as Add‑on to Metformin (± SGLT‑2 Inhibitor) in Adults with Type 2 Diabetes Not Controlled by Metformin

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Semaglutide
  • Sponsor:Amgen Inc.

Cardiac failure

Not yet recruiting

Efficacy and Safety of Fixed‑Dose Combination of Dapagliflozin, Bisoprolol Fumarate, and Eplerenone vs Usual Care in Hospitalized Acute Heart Failure Patients

InvestigationalNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Bisoprolol Fumarate
  • Sponsor:Institut De Recherches Internationales Servier IRIS

Cardiovascular disorder+2

Not yet recruiting

Phase III Study Evaluating Efficacy and Safety of Petrelintide in Participants with Overweight or Obesity and Established Cardiovascular Disease

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Petrelintide
  • Sponsor:F. Hoffmann-La Roche AG

Prostate cancer metastatic

Not yet recruiting

Study of saruparib plus AR inhibitor drug combination in men with metastatic hormone‑sensitive prostate cancer previously treated with docetaxel or Lu‑PSMA and PSA ≥0.2 ng/mL

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone Acetate
  • Sponsor:Astrazeneca AB

Interstitial lung disease+1

Not yet recruiting

Safety and Efficacy of Mirivadelgat Compared with Placebo in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Mirivadelgat
  • Sponsor:Foresee Pharmaceuticals USA Inc.

Other cities in Hungary

The busiest research cities in the country

All 73 cities in Hungary

Clinical research in Deszk

What the registry says about research in the country

01 Lung Cancer Research

Innovative clinical trials focusing on non-small cell lung cancer (NSCLC) treatments, particularly targeting advanced and unresectable cases.

  • Advanced Non-Squamous NSCLC with HER2 Mutations
  • Stage III Unresectable NSCLC
  • Combination Therapy Approaches

Studies evaluating novel therapeutic agents including zongertinib and combination treatments with durvalumab plus domvanalimab to improve patient outcomes.

02 Targeted Therapies

Research examining personalized treatment approaches for patients with specific genetic markers and protein expressions.

  • HER2 Mutation-Targeted Treatments
  • PD-L1 Expression Analysis
  • Immunotherapy Combinations

Investigations comparing new targeted therapies against standard-of-care treatments for better progression-free survival.

03 Treatment Innovation

Advancement in therapeutic strategies for locally advanced lung cancer patients.

  • Chemoradiation Therapy
  • Novel Drug Combinations
  • Biomarker-Driven Research

Focus on developing improved treatment options for patients with unresectable stage III NSCLC following concurrent chemoradiation.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.